277 related articles for article (PubMed ID: 36446777)
1. Chronic lymphocytic leukemia treatment algorithm 2022.
Hampel PJ; Parikh SA
Blood Cancer J; 2022 Nov; 12(11):161. PubMed ID: 36446777
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia treatment algorithm 2018.
Parikh SA
Blood Cancer J; 2018 Oct; 8(10):93. PubMed ID: 30283014
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
4. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
6. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.
Moia R; Patriarca A; Schipani M; Gaidano G
Cancer J; 2021 Jul-Aug 01; 27(4):266-274. PubMed ID: 34398553
[TBL] [Abstract][Full Text] [Related]
7. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Banerji V; Aw A; Robinson S; Doucette S; Christofides A; Sehn LH
Curr Oncol; 2020 Dec; 27(6):e645-e655. PubMed ID: 33380880
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
9. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
10. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
11. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
13. Prognostication in chronic lymphocytic leukemia.
Moia R; Gaidano G
Semin Hematol; 2024 Apr; 61(2):83-90. PubMed ID: 38523019
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages.
Robak P; Robak T
Expert Opin Biol Ther; 2023 Jan; 23(1):21-35. PubMed ID: 36374125
[TBL] [Abstract][Full Text] [Related]
17. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
18. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
Yeung CCS; Shadman M
Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
[TBL] [Abstract][Full Text] [Related]
19. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
Rainone M; Siddiqi T
Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]